Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3Genitourinary 2Breast 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Other 1Endocrine 1Classical hematology 1

Conditions

Prostatic Neoplasms 1Multiple Endocrine Neoplasia Type 1 1

Interventions

Everolimus 25Magnetic Resonance Spectroscopy 13pembrolizumab 12pasireotide 12Sunitinib 11Octreotide 11lanreotide 10cabozantinib 10lenvatinib 8Sorafenib 8Cisplatin 8Temozolomide 7Etoposide 7Bevacizumab 7pazopanib 6Paclitaxel 6Nivolumab 6Doxorubicin 6Carboplatin 6Capecitabine 6vandetanib 5gallium Ga 68 dotatate 5Specimen Handling 5trametinib 4lutetium Lu 177 dotatate 4dabrafenib 4Mitotane 4Iodine-131 4telotristat ethyl 3surufatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Glutamine × Endocrine × Clear all
NCT01607879 2023-09-22

Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation

Medical College of Wisconsin

Phase 2 Completed
48 enrolled 15 charts
EndocrineGenitourinary

Prostatic Neoplasms, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡